摘要
非奈利酮是一种新型非甾体类盐皮质激素受体拮抗剂,通过抗氧化、抗炎、抗纤维化等作用对2型糖尿病合并慢性肾病起防治作用,并且具有显著的心血管保护作用。与传统盐皮质激素受体拮抗剂相比具有更高的选择性。本文对非奈利酮的基本介绍、基础研究、临床研究、局限性等进行了综述,目的是为2型糖尿病合并慢性肾病的治疗提供更多思路和选择。
Finerenone is a new non-steroidal mineralocorticoid receptor antagonists,which can prevent and treat type 2 diabetes mellitus complicated with chronic kidney disease through antioxidant,anti-inflammatory and anti-fibrosis effects,and has a significant cardiovascular protection effect.Compared with traditional mineralocorticoid receptor antagonists,finerenone has a higher selectivity.In this review,the basic introduction,basic research,clinical research and limitations of finerenone were reviewed in order to provide more ideas and options for the treatment of type 2 diabetes mellitus complicated with chronic kidney disease.
作者
翟葳葳
余巧玲
刘平
邱博
吴惠珍
ZHAI Weiwei;YU Qiaoling;LIU Ping;QIU Bo;WU Huizhen(Graduate School of Hebei Medical University,Shijiazhuang 050017,Hebei,China;Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,Hebei,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2022年第9期1067-1074,共8页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
河北省自然科学基金青年基金项目(H2020307020)。
关键词
非奈利酮
2型糖尿病合并慢性肾病
盐皮质激素受体拮抗剂
finerenone
type 2 diabetes mellitus with chronic kidney disease
mineralocorticoid receptor antagonists